As extrapyramidal side effects of typical antipsychotics compelled clinicians to move towards the atypical ones, these newer, so- called novel agents have brought with them a gamut of adversities,the various metabolic side effects. The study will include 120 patients, both indoor and outdoor, suffering from schizophrenia, diagnosed using the ICD-10 criteria. The patients will be grouped into three categories, i.e. control group and two study groups, control group having 30 patients and study groups with 45 patients each. The average weight gains in the three drug groups show a mean of 61.8 in the Haloperidol group with a mean average increase of 2.9 kgs over a period of 18 months, as compared to mean increases in weight with Olanzapine being 14.6 kgs and for Risperidone 10.9 kgs. All the three groups have significant p-values(<0.0001) for increase in weight over the 18 month period.